SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is seeing heightened investor attention amid escalating Middle East tensions, following reports of a drone strike on Saudi Arabia's largest oil refinery and fears over the Strait of Hormuz. The community is actively discussing its potential for a significant short squeeze and a parabolic price run, drawing comparisons to past oil rallies driven by geopolitical events.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. (BATL) is soaring amidst intense discussions surrounding escalating geopolitical tensions impacting Middle Eastern oil supply and shipping, leading to a surge in crude prices. The low-float oil producer is a focal point for traders anticipating a significant short squeeze due to high short interest and heightened market volatility.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing a massive price surge driven by strong earnings and bullish guidance for its 800G transceiver demand from hyperscale data centers, leading to multiple analyst upgrades in the optical networking sector. The community is keenly debating whether the stock's parabolic move reflects genuine long-term potential in AI infrastructure or if it's an overvalued pump-and-dump susceptible to dilution from a recent stock offering.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as the critical role of photonics in AI infrastructure draws intensified investor focus, evidenced by recent significant institutional stakes, though community sentiment remains split between high conviction in its optical interconnect technology and impatience for tangible commercialization ahead of the upcoming OFC conference.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is surging amidst heightened geopolitical tensions from reported U.S.-Israeli strikes on Iran and subsequent retaliatory attacks, driving community discussion around severe oil supply disruptions if the Strait of Hormuz remains impacted, with many anticipating a significant price surge.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is trending sharply lower after the FDA indicated that Phase I/II data for its Huntington's disease gene therapy, AMT-130, are insufficient for approval, recommending a larger, sham-controlled Phase III trial. The community is actively debating this regulatory setback, questioning the FDA's "moving goalposts" and commitment to accelerating treatments for rare diseases.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending following a solid Q4 earnings beat and a new five-year LNG supply agreement with Trafigura, reinforcing its strong growth trajectory. The community is actively discussing the stock's significant undervaluation compared to its rapidly expanding LNG capacity, emphasizing its strategic advantage in the spot market amid escalating geopolitical tensions in the Strait of Hormuz, which could further drive up global LNG prices and potentially trigger a short squeeze.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Escalating geopolitical tensions in the Middle East, marked by drone strikes on key energy facilities and reports of shipping disruptions in the Strait of Hormuz, are fueling widespread speculation about rapidly rising oil prices. The community is largely bullish on Exxon Mobil, viewing it as a direct beneficiary of the heightened risk premium and anticipating significant upside for the broader energy sector.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is capturing market attention as escalating US-Iran tensions and potential disruptions in the Strait of Hormuz drive strong safe-haven flows, leading community discussion around gold's role as a critical hard asset during geopolitical uncertainty.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending due to a strategic agreement with NVIDIA, which includes a significant investment and commitment for advanced optical components, positioning the company as a key player in the expanding AI data center infrastructure, while community discussions highlight both significant upside and concerns about its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSA Capital Partners LLP Trims Stock Position in Praxis Precision Medicines, Inc. $PRAX

GSA Capital Partners LLP cut its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 52.2% during the 3rd quarter, according to its most recent 13F filing with the Securities...

Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Wolfe Research

Wolfe Research raised shares of Praxis Precision Medicines to a "strong-buy" rating in a report on Monday...

3,826 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by ProShare Advisors LLC

ProShare Advisors LLC acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the third quarter, according to the company in its most recent disclosure with the...

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year

Key PointsBaker Bros. Advisors LP added 437,000 shares of Praxis Precision Medicines in the fourth quarter; the estimated transaction value is $81.38 million based on quarterly average pricing...

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

Key PointsPerceptive Advisors purchased 431,432 Praxis Precision Medicines shares in the fourth quarter; the estimated trade size was $80.34 million (based on the mean unadjusted close for the...

<ul class="summary-bullets"><li>Truist raised the firm's price target on Praxis Precision to $700 from $500 and maintained a ‘Buy’ rating on the shares.</li><li>Wells Fargo said it is surprised that priority review wasn't requested for Ulixadolid given the drug's Breakthrough Therapy Designation.</li><li>Wedbush continues to hold reservations on the ulixacaltamide filing.</li></ul><p><br>Shares of Praxis Precision Medicines, Inc. (PRAX) rallied 2% on Friday after analysts hiked their price targets on the stock, one as much as $700. The hikes come amid optimism spurred by the company’s recent submissions to the U.S. Food and Drug Administration.</p><p>Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of the neurodevelopmental disorder called Developmental and Epileptic Encephalopathy. Both the experimental drugs were previously granted the Breakthrough Therapy Designation by the FDA.</p><p>“Pending their expected positive reviews, we will be positioned to transition into a commercial company,” said Praxis CEO Marcio Souza. “The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years. Together, these four assets have a revenue potential of over $20 billion.”</p><h2 class="st-heading-2">Analysts React</h2><p>Subsequently, Wedbush raised the firm's price target on Praxis Precision to $130 from $95 and kept an ‘Underperform’ rating on the shares, according to TheFly. The firm said that the most notable in the Q4 2025 update was that management completed submissions for both ulixacaltamide and relutrigine. Acceptance of the application likely arrives mid-April, while management requested priority review solely for relutrigine, not ulixacaltamide, the firm noted. Wedbush continues to hold reservations on the ulixacaltamide filing.</p><p>Wells Fargo, meanwhile, raised the firm's price target on Praxis Precision to $305 from $282 and kept an ‘Equal Weight’ rating on the shares. The firm recently initiated coverage with the view that risk/reward is balanced heading into the Ulixadolid FDA review. It further added that it is surprised that priority review wasn't requested given the drug's Breakthrough Therapy Designation.</p><p>Truist, meanwhile, raised the firm's price target on Praxis Precision to $700 from $500 and maintained a ‘Buy’ rating on the shares. The company's Q4 update was "notable" for its completed NDA submissions, the analyst told investors in a research note.</p><h2 class="st-heading-2">Praxis’ Financial Position</h2><p>On Thursday, Praxis reported net loss per share of $3.5 for the fourth quarter (Q4), compared to an analyst estimate of $3.1</p><p>The company ended 2025 with $926.1 million in cash, cash equivalents and marketable securities. This, coupled with the $621.2 proceeds from a Jan. 2026 follow-on public offering, are expected to fund operations into 2028, the company said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around PRAX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</p><p>According to data from Koyfin, the average 12-month price target on the stock is $599.94, representing a potential upside of about 81% from the last closing price.</p><p><a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> has more than quadrupled in value over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock

Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of Developmental and Epileptic Encephalopathy.

Equity

Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of Developmental and Epileptic Encephalopathy.


Praxis Precision Medicines (NASDAQ:PRAX) Sets New 1-Year High Following Analyst Upgrade

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 1-Year High on Analyst Upgrade...

Truist Financial Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock

Truist Financial raised their price target on Praxis Precision Medicines from $500.00 to $700.00 and gave the company a "buy" rating in a report on Friday...

Praxis Precision Medicines (NASDAQ:PRAX) Posts Earnings Results, Misses Estimates By $0.50 EPS

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) announced its earnings results on Thursday. The company reported ($3.50) earnings per share for the quarter, missing the consensus estimate...

Praxis Precision Medicines Q4 Earnings Call Highlights

Praxis Precision Medicines (NASDAQ:PRAX) used its fourth-quarter and full-year 2025 earnings call to highlight multiple regulatory and clinical milestones across its central nervous system portfolio...

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

PRAX
Praxis Precision Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PRAX News

PRAXPraxis Precision Medicines Inc